ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
22 avr. 2024 16h31 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA...
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
19 janv. 2024 07h00 HE
|
ProQR Therapeutics N.V.
Platform demonstrates robust in vivo editing capabilities reporting up to 70% editing of ACTB in the liver of non-human primates (NHPs) and miceFunctional effect demonstrated in mice in vivo via...
IMUNON Reminds Investors of its Virtual R&D Day Tomorrow at 4:00 p.m. ET
13 sept. 2023 08h30 HE
|
Imunon, Inc.
Program will feature executive management plus key opinion leaders in immuno-oncology and vaccine development LAWRENCEVILLE, N.J., Sept. 13, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a...
ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit
06 juil. 2023 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., July 06, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA...
ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023
09 mai 2023 08h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA...
ProQR to Present at Upcoming Scientific and Industry Conferences
07 mars 2023 08h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA...
Inventiva annonce la présentation de trois abstracts scientifiques lors de l’EASL International Liver Congress™ 2022
09 juin 2022 16h00 HE
|
INVENTIVA
Trois présentations par poster démontrant : les effets bénéfiques de lanifibranor sur les marqueurs de la santé cardiométabolique chez les patients atteints de NASH avec fibrose non cirrhotique,...
Inventiva announces three scientific presentations at the EASL International Liver Congress™ 2022
09 juin 2022 16h00 HE
|
INVENTIVA
Three poster presentations showing the beneficial effects of lanifibranor on markers of cardiometabolic health in patients with non-cirrhotic NASH fibrosis independent of weight gain observed.the...